<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03554772</url>
  </required_header>
  <id_info>
    <org_study_id>DFN-15-CD-010</org_study_id>
    <nct_id>NCT03554772</nct_id>
  </id_info>
  <brief_title>Efficacy, Tolerability, Safety, and Pharmacokinetic Study of DFN-15</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability, Safety and Pharmacokinetic Study of Single Doses of DFN-15 in Post-Surgical Dental Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy, Tolerability, Safety and Pharmacokinetic Study of DFN-15 in Post-Surgical Dental&#xD;
      Pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, single-center, randomized, double blind, dose-ranging placebo-controlled,&#xD;
      clinical study evaluating the efficacy, tolerability, safety, and the pharmacokinetic&#xD;
      properties of a known drug (selective COX-2 inhibitor) administered as an alternative&#xD;
      formulation/dosage form (DFN-15, a liquid oral formulation) in an accepted model of acute&#xD;
      post-operative pain (acute pain following oral surgery for extraction of bilateral impacted&#xD;
      mandibular third molar teeth in otherwise healthy subjects).120 female and male healthy&#xD;
      subjects scheduled to undergo elective bilateral third molar extraction will be randomized,&#xD;
      after they provide informed consent and are confirmed to meet all the study selection&#xD;
      criteria, in a 1:1:1:1 ratio to receive a single oral dose of either DFN-15 Dose A DFN-15&#xD;
      Dose B, DFN-15 Dose C or matching placebo.&#xD;
&#xD;
      Subjects will undergo a screening procedure (within 28 days of the scheduled extraction of&#xD;
      the impacted third molars) that will involve the collection of demographic information,&#xD;
      height, weight and body mass index (BMI), urine pregnancy test (women of child-bearing&#xD;
      potential,) medical and medicinal history, physical examination, dental examination, vital&#xD;
      signs measurement (blood pressure, pulse rate, respiratory rate), clinical laboratory&#xD;
      investigation (hematology,serology, coagulation parameters, serum chemistry and&#xD;
      urinalysis),12-lead ECG and a panoramic x-ray to document the impacted mandibular third molar&#xD;
      teeth. As a pre-requisite for randomization, subjects will be required to report &quot;moderate&quot;&#xD;
      to &quot;severe&quot; baseline pain on the provided paper diary within 6 hours post-surgery (called the&#xD;
      'Baseline' period) as characterized on a 4-point categorical pain intensity (PI) scale (0=&#xD;
      none, 1= mild, 2= moderate, 3= severe), and a score of ≥5, on the 11-point Numerical Pain&#xD;
      Rating Scale (NPRS) where 0 represents 'no pain' and 10 represents 'worst pain imaginable'.&#xD;
      Eligible subjects will be randomized and will receive a single dose of the assigned study&#xD;
      treatment. Subjects will be randomized and administered the study medication within 15&#xD;
      minutes of meeting the post-operative inclusion criteria (baseline score).Subjects will be&#xD;
      assessed at pre-specified time-points over an observation period of 8 hours from the time of&#xD;
      randomization.&#xD;
&#xD;
      Subjects with inadequately controlled pain symptoms may request rescue analgesic medication.&#xD;
      Subjects will be encouraged to delay using the rescue medication if their pain is tolerable&#xD;
      until 120 minutes post-dose of study medication. A subject who is administered rescue pain&#xD;
      medication will continue completing pain assessments until 8 hours after treatment&#xD;
      initiation. All randomized subjects will be provided with a paper diary to record pain&#xD;
      assessments (Pain Intensity on 11-point NPRS scale, followed by Pain Relief using a 5-point&#xD;
      categorical scale [where 0= no pain relief, 1= little pain relief, 2= some pain relief, 3= a&#xD;
      lot of pain relief, 4= complete pain relief]) At study medication administration, two&#xD;
      stopwatches will be started, to measure times to 'perceptible' and 'meaningful' pain-relief.&#xD;
      Subjects will be instructed to stop the first stopwatch when they first perceive pain relief&#xD;
      to occur (time to perceptible relief). Subjects will be instructed to stop the second&#xD;
      stopwatch when they first experience meaningful pain relief (time to meaningful relief).&#xD;
      Stopwatch times of perceptible relief and meaningful relief will be recorded using exact&#xD;
      stopwatch time displayed.&#xD;
&#xD;
      In addition, at 8 hours post-dose or within 5 minutes prior to first use of rescue medication&#xD;
      (whichever is earlier), subjects will be asked to record within the provided patient diary:&#xD;
      'Patient Rating of Treatment Satisfactoriness' using a 5-point verbal rating scale (0 =poor,&#xD;
      1 =fair, 2 =good, 3=very good, 4 =excellent).&#xD;
&#xD;
      Subjects will remain NPO (nothing by mouth), including water, from Check-in (i.e., at least 2&#xD;
      hours before the administration of the dose of study medication to randomized subjects) until&#xD;
      2 hours post-dose, on Day 1 (study day). After 2 hours post-dose, subjects may be permitted&#xD;
      to consume water, or gelatin snacks. Subjects are prohibited from ingesting solid foods or&#xD;
      carbonated beverages for at least 6 hours post-dose.&#xD;
&#xD;
      12-lead ECG and Vital Signs were performed before surgery, at baseline and at periodic&#xD;
      intervals post-dose until 8 hours .At discharge (8 hours post-randomization) from the&#xD;
      clinical facility, all AEs reported for the subjects will be reviewed. A physical&#xD;
      examination, including evaluation of the incision site for hematomas, and clinical laboratory&#xD;
      evaluation (coagulation parameters and specific hematology, serum biochemistry and urinalysis&#xD;
      parameters) will be conducted.&#xD;
&#xD;
      All subjects will have blood drawn at specified time points (pre-dose and over the 8 hour&#xD;
      observation period) for pharmacokinetic evaluation.&#xD;
&#xD;
      Subjects will return to the research center 7 days (± 3 days) post-surgery for evaluation of&#xD;
      their safety and well-being. Any AEs experienced post-surgery will be reviewed. A physical&#xD;
      examination, of the subject will be performed, 12-lead ECG, and vital signs parameters will&#xD;
      be repeated. Hematology, coagulation parameters, serum biochemistry and urinalysis parameters&#xD;
      will be repeated only if there is a clinically significant abnormality or ongoing AE(s). Any&#xD;
      changes to the prior and concomitant medication made after discharge will be reviewed and&#xD;
      recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2018</start_date>
  <completion_date type="Actual">August 20, 2018</completion_date>
  <primary_completion_date type="Actual">August 20, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Summed Pain Intensity Difference Over the First Six Hours</measure>
    <time_frame>6 hours post dose</time_frame>
    <description>The primary endpoint is the Summed Pain Intensity Difference over the first 6 hours (SPID6) after dosing compared between DFN-15 and placebo. Pain intensity (P) will be measured at timepoints of 15, 30, and 45 minutes and 1, 1.5, 2, 3, 4, 5 and 6, hours after baseline ,using 11-point Pain Intensity Numerical Rating Scale (NPRS). Zero (0) equals no pain and Ten (10) equals worst pain imaginable.&#xD;
SPID6 is created by summing the time weighted pain intensity differences (PID) scores using the area under the PID curve methodology. All SPID calculations will be performed using the standard trapezoidal rule SPIDx =∑_(i=0)^x▒((〖PID〗_i+〖PID〗_(i+1))/2) * (T_(i+1)- T_i ) Where: PID_i = P_i - PBL (Pain score at time i and Pain score at Baseline), and (T_i+1 - T_i) is the Time difference in minutes between time i and time i+1.&#xD;
Therefore, SPID6 values may theoretically range between a maximum score of 0 ( no improvement) and a minimum score of -3525 (best improvement)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>DFN-15 (Celecoxib Oral Solution) 62.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose containing 62.5 mg of celecoxib in 10 ml solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DFN-15 (Celecoxib Oral Solution) 125 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose containing 125 mg of celecoxib in 10 ml solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DFN-15 (Celecoxib Oral Solution) 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose containing 250 mg of celecoxib in 10 ml solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose containing 0 mg of celecoxib in 10 ml solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFN-15 (Celecoxib Oral Solution) 62.5 mg</intervention_name>
    <description>Oral Solution</description>
    <arm_group_label>DFN-15 (Celecoxib Oral Solution) 62.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFN-15 (Celecoxib Oral Solution) 125 mg</intervention_name>
    <description>Oral Solution</description>
    <arm_group_label>DFN-15 (Celecoxib Oral Solution) 125 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFN-15 (Celecoxib Oral Solution) 250 mg</intervention_name>
    <description>Oral Solution</description>
    <arm_group_label>DFN-15 (Celecoxib Oral Solution) 250 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects scheduled to undergo elective bilateral lower (mandibular) third molar&#xD;
             extraction under local anesthesia.&#xD;
&#xD;
          2. Subjects must be generally healthy, ambulatory, able to understand and willing to&#xD;
             comply with study procedures, study restrictions, assessments, and requirements per&#xD;
             the discretion of the investigator.&#xD;
&#xD;
          3. Subjects must voluntarily sign written informed consent prior to any study-specific&#xD;
             procedures.&#xD;
&#xD;
          4. Subjects must have a body mass index (BMI) greater than or equal to 19.0 to less than&#xD;
             or equal to 35.0&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of migraine or frequent headaches, low back pain, or other acute or chronic&#xD;
             pain conditions.&#xD;
&#xD;
          2. Acute illness or unresolved local infection prior to surgery that can interfere with&#xD;
             the conduct of the study.&#xD;
&#xD;
          3. Positive results on urine drug screen or alcohol breath test indicative of illicit&#xD;
             drug (Cocaine Metabolites, Marijuana (THC), MDMA (Ecstasy) and Phencyclidine) or&#xD;
             alcohol abuse at screening and/or prior to extraction procedure.&#xD;
&#xD;
          4. Positive results for the following (prescription included): Amphetamines,&#xD;
             Barbiturates, Benzodiazepines, Methadone, Methamphetamine, Opiates, Oxycodone, and&#xD;
             Tricyclic Antidepressants.&#xD;
&#xD;
          5. Frequent use of nicotine-containing products.&#xD;
&#xD;
          6. Excessive intake of caffeine-containing foods or beverages within 48 hours prior to&#xD;
             surgery.&#xD;
&#xD;
          7. Routinely uses pain medication.&#xD;
&#xD;
          8. Currently taking any corticosteroid chronically (except for an inhaled steroid for&#xD;
             pulmonary disease, and local topical or ophthalmic steroid) or has taken systemic&#xD;
             corticosteroids within 4 weeks of the proposed date of surgery.&#xD;
&#xD;
          9. Currently taking central nervous system active drugs such as hypnotics, sedatives,&#xD;
             monoamine oxidase inhibitors, sympathomimetic amines, benzodiazepines, tricyclic&#xD;
             antidepressants, or serotonin norepinephrine reuptake inhibitors, and anticonvulsants&#xD;
             for pain.&#xD;
&#xD;
         10. Donated blood products or had blood loss greater than 500 mL 30 days prior to&#xD;
             Screening or between Screening and surgery.&#xD;
&#xD;
         11. Member or relative of study staff or the Sponsor directly involved in the study.&#xD;
&#xD;
         12. Previous participation in this study.&#xD;
&#xD;
         13. Has received another new chemical entity (defined as a compound which has not been&#xD;
             approved for marketing) or has participated in any other clinical study that included&#xD;
             drug treatment within 30 days prior to the Screening visit.&#xD;
&#xD;
         14. Currently receiving or have received within 7 days prior to investigational product&#xD;
             administration in the study, any drug (s) that is metabolized by hepatic microsomal&#xD;
             enzyme CYP 2D6.&#xD;
&#xD;
         15. Clinically significant disease or disorder which may put the subject at risk,&#xD;
             influence the results or the subject's ability to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elimor Brand-Schieber, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Director-Clinical Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 101</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 21, 2018</study_first_submitted>
  <study_first_submitted_qc>May 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <results_first_submitted>December 31, 2020</results_first_submitted>
  <results_first_submitted_qc>January 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2021</results_first_posted>
  <disposition_first_submitted>September 9, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>September 16, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 20, 2019</disposition_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT03554772/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT03554772/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Single dose containing 0 mg of celecoxib in 10 ml solution&#xD;
Placebo: Oral Solution</description>
        </group>
        <group group_id="P2">
          <title>DFN-15 (Celecoxib Oral Solution) 62.5 mg</title>
          <description>Single dose containing 62.5 mg of celecoxib in 10 ml solution&#xD;
DFN-15 (Celecoxib Oral Solution) 62.5 mg: Oral Solution</description>
        </group>
        <group group_id="P3">
          <title>DFN-15 (Celecoxib Oral Solution) 125 mg</title>
          <description>Single dose containing 125 mg of celecoxib in 10 ml solution&#xD;
DFN-15 (Celecoxib Oral Solution) 125 mg: Oral Solution</description>
        </group>
        <group group_id="P4">
          <title>DFN-15 (Celecoxib Oral Solution) 250 mg</title>
          <description>Single dose containing 250 mg of celecoxib in 10 ml solution&#xD;
DFN-15 (Celecoxib Oral Solution) 250 mg: Oral Solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment Period (8 Hours Post Dose)</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Single dose containing 0 mg of celecoxib in 10 ml solution&#xD;
Placebo: Oral Solution</description>
        </group>
        <group group_id="B2">
          <title>DFN-15 (Celecoxib Oral Solution) 62.5 mg</title>
          <description>Single dose containing 62.5 mg of celecoxib in 10 ml solution&#xD;
DFN-15 (Celecoxib Oral Solution) 62.5 mg: Oral Solution</description>
        </group>
        <group group_id="B3">
          <title>DFN-15 (Celecoxib Oral Solution) 125 mg</title>
          <description>Single dose containing 125 mg of celecoxib in 10 ml solution&#xD;
DFN-15 (Celecoxib Oral Solution) 125 mg: Oral Solution</description>
        </group>
        <group group_id="B4">
          <title>DFN-15 (Celecoxib Oral Solution) 250 mg</title>
          <description>Single dose containing 250 mg of celecoxib in 10 ml solution&#xD;
DFN-15 (Celecoxib Oral Solution) 250 mg: Oral Solution</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="29"/>
            <count group_id="B4" value="31"/>
            <count group_id="B5" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.9" spread="2.70"/>
                    <measurement group_id="B2" value="19.6" spread="2.45"/>
                    <measurement group_id="B3" value="19.2" spread="1.64"/>
                    <measurement group_id="B4" value="20.5" spread="2.45"/>
                    <measurement group_id="B5" value="19.8" spread="2.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body Mass Index is calculated as Weight (in kg)/ Height (in m) ^ 2</description>
          <units>kg/ m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.4" spread="4.15"/>
                    <measurement group_id="B2" value="27.1" spread="5.03"/>
                    <measurement group_id="B3" value="25.1" spread="4.11"/>
                    <measurement group_id="B4" value="24.4" spread="4.41"/>
                    <measurement group_id="B5" value="25.8" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Qualifying Baseline Categorical Pain Score</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0 = No Pain</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1= Mild Pain</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2= Moderate Pain</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3= Severe Pain</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Summed Pain Intensity Difference Over the First Six Hours</title>
        <description>The primary endpoint is the Summed Pain Intensity Difference over the first 6 hours (SPID6) after dosing compared between DFN-15 and placebo. Pain intensity (P) will be measured at timepoints of 15, 30, and 45 minutes and 1, 1.5, 2, 3, 4, 5 and 6, hours after baseline ,using 11-point Pain Intensity Numerical Rating Scale (NPRS). Zero (0) equals no pain and Ten (10) equals worst pain imaginable.&#xD;
SPID6 is created by summing the time weighted pain intensity differences (PID) scores using the area under the PID curve methodology. All SPID calculations will be performed using the standard trapezoidal rule SPIDx =∑_(i=0)^x▒((〖PID〗_i+〖PID〗_(i+1))/2) * (T_(i+1)- T_i ) Where: PID_i = P_i - PBL (Pain score at time i and Pain score at Baseline), and (T_i+1 - T_i) is the Time difference in minutes between time i and time i+1.&#xD;
Therefore, SPID6 values may theoretically range between a maximum score of 0 ( no improvement) and a minimum score of -3525 (best improvement)</description>
        <time_frame>6 hours post dose</time_frame>
        <population>mITT Population : defined as all randomized subjects who received study drug and recorded at least one post-dosing PI score</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose containing 0 mg of celecoxib in 10 ml solution&#xD;
Placebo: Oral Solution</description>
          </group>
          <group group_id="O2">
            <title>DFN-15 (Celecoxib Oral Solution) 62.5 mg</title>
            <description>Single dose containing 62.5 mg of celecoxib in 10 ml solution&#xD;
DFN-15 (Celecoxib Oral Solution) 62.5 mg: Oral Solution</description>
          </group>
          <group group_id="O3">
            <title>DFN-15 (Celecoxib Oral Solution) 125 mg</title>
            <description>Single dose containing 125 mg of celecoxib in 10 ml solution&#xD;
DFN-15 (Celecoxib Oral Solution) 125 mg: Oral Solution</description>
          </group>
          <group group_id="O4">
            <title>DFN-15 (Celecoxib Oral Solution) 250 mg</title>
            <description>Single dose containing 250 mg of celecoxib in 10 ml solution&#xD;
DFN-15 (Celecoxib Oral Solution) 250 mg: Oral Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Summed Pain Intensity Difference Over the First Six Hours</title>
          <description>The primary endpoint is the Summed Pain Intensity Difference over the first 6 hours (SPID6) after dosing compared between DFN-15 and placebo. Pain intensity (P) will be measured at timepoints of 15, 30, and 45 minutes and 1, 1.5, 2, 3, 4, 5 and 6, hours after baseline ,using 11-point Pain Intensity Numerical Rating Scale (NPRS). Zero (0) equals no pain and Ten (10) equals worst pain imaginable.&#xD;
SPID6 is created by summing the time weighted pain intensity differences (PID) scores using the area under the PID curve methodology. All SPID calculations will be performed using the standard trapezoidal rule SPIDx =∑_(i=0)^x▒((〖PID〗_i+〖PID〗_(i+1))/2) * (T_(i+1)- T_i ) Where: PID_i = P_i - PBL (Pain score at time i and Pain score at Baseline), and (T_i+1 - T_i) is the Time difference in minutes between time i and time i+1.&#xD;
Therefore, SPID6 values may theoretically range between a maximum score of 0 ( no improvement) and a minimum score of -3525 (best improvement)</description>
          <population>mITT Population : defined as all randomized subjects who received study drug and recorded at least one post-dosing PI score</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-420.2" spread="716.42"/>
                    <measurement group_id="O2" value="-1101.0" spread="570.74"/>
                    <measurement group_id="O3" value="-1771.7" spread="646.10"/>
                    <measurement group_id="O4" value="-1463.5" spread="727.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value for each dose group vs placebo comparison</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model included treatment as main effect , baseline NPRS and basline BMI as covariates P-value is Dunnett adjusted (individual treatment arms)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All AEs, whether volunteered, elicited, or noted on physical examination, and regardless of causality or seriousness, were assessed and recorded in the CRF beginning after administration of study drug through the final follow-up assessment (approximately 7 ± 3 days after the last study drug administration). Additionally, if the investigator became aware of the occurrence of an SAE within 30 days of the last visit, the SAE was reported.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Single dose containing 0 mg of celecoxib in 10 ml solution&#xD;
Placebo: Oral Solution</description>
        </group>
        <group group_id="E2">
          <title>DFN-15 (Celecoxib Oral Solution) 62.5 mg</title>
          <description>Single dose containing 62.5 mg of celecoxib in 10 ml solution&#xD;
DFN-15 (Celecoxib Oral Solution) 62.5 mg: Oral Solution</description>
        </group>
        <group group_id="E3">
          <title>DFN-15 (Celecoxib Oral Solution) 125 mg</title>
          <description>Single dose containing 125 mg of celecoxib in 10 ml solution&#xD;
DFN-15 (Celecoxib Oral Solution) 125 mg: Oral Solution</description>
        </group>
        <group group_id="E4">
          <title>DFN-15 (Celecoxib Oral Solution) 250 mg</title>
          <description>Single dose containing 250 mg of celecoxib in 10 ml solution&#xD;
DFN-15 (Celecoxib Oral Solution) 250 mg: Oral Solution</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Wolff-Parkinson-White syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Alveolar Osteitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Bilirubin Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood Creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood Urine Present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cardiac Murmur</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Glomerular Filtration Rate decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hematocrit decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>International Normalized Ratio increaed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Srinivas Shenoy B.</name_or_title>
      <organization>Dr Reddy's Laboratories, Inc.</organization>
      <phone>6099550249</phone>
      <email>srinivasshenoyb@drreddys.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

